業績

当教室関連研究の英文論文

2010年

Kobayashi T, Kuroda J, Shimura K, Akaogi T, Kawata E, Kiyota M, Tanaka T, Kamitsuji Y, Murakami S, Hatsuse M, Okano A, Iwai T, Ueda S, Koshida M, Uchiyama H, Matsumoto Y, Uoshima N, Ueda Y, Kobayashi Y, Shimazaki C, Horiike S, Taniwaki M. Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. Int J Hematol, 92, 579-586, 2010　（京都府立医科大学血液・腫瘍内科と関連施設の共同研究）

Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Oshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a Single Institute Experience. Int J Hematol, 92:669-672, 2010

Kuroda J, Yamamoto M, Nagoshi H, Kobayashi T, Sasaki N, Shimura Y, Horiike S, Kimura S, Yamauchi A, Hirashima M, Taniwaki M.. Targeting ATF-3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia. Mol Cancer Res, 994-1001,8, 2010. （香川大学免疫病理学、京都大学輸血細胞治療部との共同研究）

Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Dr. Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Leukemia, 843-850, 24, 2010.（香川大学免疫病理学、京都大学輸血細胞治療部との共同研究）

Takada H, Wakabayashi N, Dohi O, Yasui K, Sakakura C, Mitsufuji S, Taniwaki M, Yoshikawa T. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet Cytogenet. 2010 Feb;197(1):16-24. （本学消化器内科学教室との共同研究）

Ikawa K, Morikawa N, Ohge H, Ikeda K, Sueda T, Taniwaki M, Kurisu K. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother. 2010 Feb;16(1):25-32. (広島大学との共同研究) Uchiyama H, Sowa Y, Wakada M, Yogosawa M, Nakanishi R, Horinaka M, Shimazaki C, Taniwaki M, Sakai T. Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells. Cancer Sci. 2010 Mar;101(3):728-34. (本学分子標的癌予防医学との共同研究)

Dohi O, Takada H, Wakabayashi N, Yasui K, Sakakura C, Mitsufuji S, Naito Y, Taniwaki M, Yoshikawa T. Epigenetic silencing of RELN in gastric cancer. Int J Oncol. 2010 Jan;36(1):85-92. （本学消化器内科学教室との共同研究）

Mizutani S, Kuroda J, Shimizu D, Horiike S, Taniwaki M. Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia. Int J Hematol, 516-521, 91, 2010.

Matsumoto Y, Horiike S, Ohshiro M, Yamamoto M, Sasaki N, Tsutsumi Y, Kobayashi T, Shimizu D, Uchiyama H, Kuroda J, Nomura K, Shimazaki C, Taniwaki M. Expression of master regulators of helper T-cell differentiation in peripheral T-cell lymphoma, not otherwise specified, by immunohistochemical analysis. Am J Clin Pathol. 281-290, 133, 2010.

Takeuchi M, Kimura S, Kuroda J, Ashihara E, Kawatani M, Osada H, Umezawa K, Yasui E, Imoto M, Tsuruo T, Yokota A, Tanaka R, Nagao R, Nakahata T, Fujiyama Y, Maekawa T. Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in hypoxic environment. Cell Death Differ, 2010 Jul;17(7):1211-20.（京都大学輸血細胞治療部との共同研究）

Yamamoto M, Kuroda J, Uchiyama H, Kobayashi T, Tsutsumi Y, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Matsumoto Y, Shimazaki C, Horiike S, Taniwaki M. Allogenic bone marrow transplantation with fludarabine/busulfan16 conditioning regimen and dasatinib maintenance therapy for elderly Philadelphia-positive acute/advanced leukemia patients. Leukemia Res, e111-e112, 34, 2010.

Yokota A, Kimura S, Tanaka R, Takeuchi M, Yao H, Sakai K, Nagao R, Kuroda J, Kamitsuji Y, Kawata E, Ashihara E, Maekawa T. Osteoclasts are involved in the maintenance of dormant leukemic cells. Leukemia Res, 793-9, 34, 2010（京都大学輸血細胞治療部との共同研究）

Tobinai K, Ogura M, Maruyama D, Uchida T, Uike N, Choi I, Ishizawa K, Itoh K, Ando K, Taniwaki M, Shimada N, Kobayashi K. Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma. Int J Hematol. 2010 Nov;92(4):563-70.

Tobinai K, Ogura M, Itoh K, Kinoshita T, Hotta T, Watanabe T, Morishima Y, Igarashi T, Terauchi T, Ohashi Y; All Collaborators of the IDEC-C2B8 Study Group in Japan. Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma: 7-year follow-up results. Cancer Sci. 2010 Dec;101(12):2579-85.

Gen Y, Yasui K, Zen Y, Zen K, Dohi O, Endo M, Tsuji K, Wakabayashi N, Itoh Y, Naito Y, Taniwaki M, Nakanuma Y, Okanoue T, Yoshikawa T. OX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. Cancer Genet Cytogenet. 2010 Oct 15;202(2):82-93. (本学消化器内科学教室との共同研究)

Waki F, Masuoka K, Fukuda T, Kanda Y, Nakamae M, Yakushijin K, Togami K, Nishiwaki K, Ueda Y, Kawano F, Kasai M, Nagafuji K, Hagihara M, Hatanaka K, Taniwaki M, Maeda Y, Shirafuji N, Mori T, Utsunomiya A, Eto T, Nakagawa H, Murata M, Uchida T, Iida H, Yakushiji K, Yamashita T, Wake A, Takahashi S, Takaue Y, Taniguchi S. Feasibility of Reduced-intensity Cord Blood Transplantation as Salvage Therapy for Graft Failure: Results of a Nationwide Survey of 80 Adult Patients. Biol Blood Marrow Transplant. 2011 Jun;17(6):841-51.

Kanbayashi Y, Hosokawa T, Okamoto K, Konishi H, Otsuji E, Yoshikawa T, Takagi T, Taniwaki M. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis. Anticancer Drugs. 2010 Oct;21(9):877-81.

Ogura M, Uchida T, Taniwaki M, Ando K, Watanabe T, Kasai M, Matsumoto Y, Shimizu D, Ogawa Y, Ohmachi K, Yokoyama H, Tobinai K; Japanese Bendamustine Lymphoma Study Group. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci. 2010 Sep;101(9):2054-8.

Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K, Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K. Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. J Virol. 2010 Jul;84(14):6966-77（宮崎大学生科学第一講座との共同研究）

Kanbayashi Y, Nomura K, Okamoto K, Matsumoto Y, Horiike S, Takagi T, Taniwaki M. Statistical examination to determine whether only 48-h value for serum concentration during high-dose methotrexate therapy is a predictor for clinical adverse events using ordered logistic regression analysis. Ann Hematol. 2010 Oct;89(10):965-9（岩手医科大学との共同研究）

Nomura K, Mizumachi E, Yamashita M, Ohshiro M, Komori T, Sugai M, Taniwaki M, Ishida Y. Drug susceptibility and clonality of methicillin-resistant Staphylococcus epidermidis in hospitalized patients with hematological malignancies. Ir J Med Sci. 2010 Sep;179(3):351-6.（岩手医科大学との共同研究）

Tsuji K, Yasui K, Gen Y, Endo M, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M, Tanaka S, Arii S, Okanoue T, Yoshikawa T. PEG10 is a probable target for the amplification at 7q21 detected in hepatocellular carcinoma. Cancer Genet Cytogenet. 2010 Apr 15;198(2):118-25. (本学消化器内科学教室との共同研究)

Taniguchi K, Shimazaki C, Ochiai N, Maruya E, Akatsuka Y, Ashihara E, Maekawa T, Taniwaki M, Saji H. Modified ELISPOT assay may predict T-cell hyporesponsiveness to non-inherited maternal antigens. Int J Lab Hematol. 2010 Feb;32:e163-8. （京都大学輸血細胞治療部、HLA研究所との共同研究）

2009年

Okamoto M, Hirai H, Taniguchi K, Shimura K, Inaba T, Shimazaki C, Taniwaki M, Imanishi J. Toll-like receptors (TLRs) are expressed by myeloid leukaemia cell lines, but fail to trigger differentiation in response to the respective TLR ligands. Br J Haematol. 2009 Nov;147(4):585-7. （本学微生物学教室との共同研究）

Tobinai K, Ishizawa K, Ogura M, Itoh K, Morishima Y, Ando K, Taniwaki M, Watanabe T, Yamamoto J, Uchida T, Nakata M, Terauchi T, Nawano S, Matsusako M, Hayashi M, Hotta T. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci. 2009 Oct;100(10):1951-6

Ashihara E, Kawata E, Nakagawa Y, Shimazaki C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T. β-catenin siRNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res, 2731-8, 15, 2009（京都大学輸血細胞治療部との共同研究）

Taniguchi K, Shimazaki C, Fujimoto Y, Shimura K, Uchiyama H, Matsumoto Y, Kuroda J, Horiike S, Taniwaki M. Tocilizumab is effective for pulmonary hypertension associated with multicentric Castleman's disease. Int J Hematol, 99-102, 90, 2009

Matsumoto Y, Horiike S, Sakagami J, Fujimoto Y, Taniguchi K, Shimizu D, Shimura K, Uchiyama H, Kuroda J, Nomura K, Shimazaki C, Taniwaki M. Early Ultrasonographic Diagnosis and Clinical Follow-up of Hepatic Veno-Occlusive Disease after Allogeneic Bone Marrow Transplantation in a Patient with Acute Lymphoblastic Leukemia. Intern Med,831-5, 48, 2009.

Matsumoto Y, Taki T, Fujimoto Y, Taniguchi K, Shimizu D, Shimura K, Uchiyama H, Kuroda J, Nomura K, Inaba T, Shimazaki C, Horiike S, Taniwaki M. Monosomies 7p and 12p and FLT3 internal tandem duplication: possible markers for diagnosis of T/myeloid biphenotypic acute leukemia and its clonal evolution. Int J Hematol. 352-8, 89, 2009（本学臨床分子病態・検査医学教室との共同研究）

Kuroda J, Taniwaki M. Involvement of BH3-only proteins in hematologic malignancies. Crit Rev Oncol Hematol. 303-9, 5, 2009

Kanbayashi Y, Nomura K, Fujimoto Y, Yamashita M, Ohshiro M, Okamoto K, Matsumoto Y, Horiike S, Takagi T, Ishida Y, Taniwaki M; Japan Haematology/Oncology Study (J-HOST) Group. Risk factors for infection in haematology patients treated with rituximab. Eur J Haematol. 2009 Jan;82(1):26-30. （J-HOSTとの共同研究）

Gen Y, Yasui K, Zen K, Nakajima T, Tsuji K, Endo M, Mitsuyoshi H, Minami M, Itoh Y, Tanaka S, Taniwaki M, Arii S, Okanoue T, Yoshikawa T. A novel amplification target, ARHGAP5, promotes cell spreading and migration by negatively regulating RhoA in Huh-7 hepatocellular carcinoma cells. Cancer Lett. 2009 Mar 8;275(1):27-34. （本学消化器内科学教室との共同研究）

Zen K, Yasui K, Nakajima T, Zen Y, Zen K, Gen Y, Mitsuyoshi H, Minami M, Mitsufuji S, Tanaka S, Itoh Y, Nakanuma Y, Taniwaki M, Arii S, Okanoue T, Yoshikawa T. ERK5 is a target for gene amplification at 17p11 and promotes cell growth in hepatocellular carcinoma by regulating mitotic entry. Genes Chromosomes Cancer. 2009 Feb;48(2):109-20. （本学消化器内科学教室との共同研究）

Nomura K, Fujimoto Y, Yamashita M, Morimoto Y, Ohshiro M, Sato K, Oyake T, Kowata S, Konishi H, Yoshikawa T, Ishida Y, Taniwaki M; Japan Hematology/Oncology Study (J-HOST) Group Kyoto. Absence of pseudomembranes in Clostridium difficile-associated diarrhea in patients using immunosuppression agents. Scand J Gastroenterol. 2009;44(1):74-8. （J-HOSTとの共同研究）

Endo M, Yasui K, Nakajima T, Gen Y, Tsuji K, Dohi O, Zen K, Mitsuyoshi H, Minami M, Itoh Y, Taniwaki M, Tanaka S, Arii S, Okanoue T, Yoshikawa T. Infrequent amplification of JUN in hepatocellular carcinoma. Anticancer Res. 2009 Dec;29(12):4989-94.(本学消化器内科学教室との共同研究)

Harada H, Watanabe M, Suzuki K, Yanagita S, Suzuki T, Yoshida Y, Kimura A, Tsudo M, Matsuda A, Tohyama K, Taniwaki M, Takeshita K, Takatoku M, Ozawa K. Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality. Int J Hematol. 2009 Oct;90(3):353-60.

2008年

Kuroda J, Matsumoto Y, Tanaka R, Kurita K, Kobayashi T, Shimizu D, Kimura S, Ashihara E, Horiike S, Shimazaki C, Taniwaki M. JAK2V617F-positive essential thrombocythemia and multiple myeloma with IGH/CCND1 gene translocation coexist, but originate from separate clones. Acta Haematol. 2008;120(3):177-81. （京都大学輸血細胞治療部との共同研究）

Fuchida SI, Shimazaki C, Hirai H, Akamatsu S, Yamada N, Uchida R, Okano A, Okamoto M, Inaba T, Taniwaki M. The effects of thalidomide on chemotactic migration of multiple myeloma cell lines. Int J Lab Hematol. 2008 Jun;30(3):220-9.

Kuroda J, Kamitsuji Y, Kimura S, Ashihara E, Kawata E, Nakagawa Y, Takeuichi M, Murotani Y, Yokota A, Tanaka R, Andreeff M, Taniwaki M, Maekawa T. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin. Int J Hematol. 2008 Jun;87(5):507-15. （京都大学輸血細胞治療部、MD Anderson Cancer Centerとの共同研究）

Yamamoto M, Kuroda J, Kobayashi T, Uoshima N, Taniwaki M. Renal vein lymphoma embolism in non-Hodgkin lymphoma. Int J Hematol. 2008 Dec;88(5):613-5.

Sasaki N, Kuroda J, Kawata E, Akaogi T, Kiyota M, Kobayashi Y, Taniwaki M. Thrombotic thrombocytopenic purpura associated with myelodysplastic syndrome. Int J Hematol. 2008 Nov;88(4):457-9.

Kuroda J, Kimura S, Andreeff M, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Murotani Y, Matsumoto Y, Tanaka H, Strasser A, Taniwaki M, Maekawa T. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol. 2008 Jan;140(2):181-90. （京都大学輸血細胞治療部、MD Anderson Cancer Center、The Walter & Eliza Hall Instituteとの共同研究）

Fujimoto Y, Nomura K, Fukada S, Shimizu D, Shimura K, Matsumoto Y, Horiike S, Nishida K, Shimazaki C, Abe M, Taniwaki M. Immunoglobulin light chain gene translocations in non-Hodgkin's lymphoma as assessed by fluorescence in situ hybridisation. Eur J Haematol. 2008 Feb;80(2):143-50.

Chinen Y, Taki T, Nishida K, Shimizu D, Okuda T, Yoshida N, Kobayashi C, Koike K, Tsuchida M, Hayashi Y, Taniwaki M. Identification of the novel AML1 fusion partner gene, LAF4, a fusion partner of MLL, in childhood T-cell acute lymphoblastic leukemia with t(2;21)(q11;q22) by bubble PCR method for cDNA. Oncogene. 2008 Apr 3;27(15):2249-56. （本学臨床分子病態・検査医学教室、消化器内科学教室との共同研究）

Kawata E, Ashihara E, Kimura S, Takenaka K, Sato K, Tanaka R, Yokota A, Kamitsuji Y, Takeuchi M, Kuroda J, Tanaka F, Yoshikawa T, Maekawa T. Administration of PLK-1 small interfering RNA with atelocollagen prevents the growth of liver metastases of lung cancer. Mol Cancer Ther. 2008 Sep;7(9):2904-12. （京都大学輸血細胞治療部との共同研究）

Kamitsuji Y, Kuroda J, Kimura S, Toyokuni S, Watanabe K, Ashihara E, Tanaka H, Yui Y, Watanabe M, Matsubara H, Mizushima Y, Hiraumi Y, Kawata E, Yoshikawa T, Maekawa T, Nakahata T, Adachi S. The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias. Cell Death Differ. 2008 Nov;15(11):1712-22. （京都大学発達小児科学教室、輸血細胞治療部などとの共同研究）

Okano A, Ashihara E, Shimazaki C, Uchiyama H, Inaba T, Taniguchi K, Maekawa T, Taniwaki M. Predictive parameters for granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. J Clin Apher. 2008;23(6):171-7. （本学臨床分子病態・検査医学教室との共同研究）

Kaneko H, Yamashita M, Ohshiro M, Ohkawara Y, Matsumoto Y, Nomura K, Horiike S, Yokota S, Taniwaki M. Protein-losing enteropathy in a case of nodal follicular lymphoma without a gastrointestinal mucosal lesion. Intern Med. 2008;47(24):2171-3.

Shimura K, Ashihara E, Shimazaki C, Matsunaga S, Taniguchi K, Uchiyama H, Matsumoto Y, Kimura S, Matsubara H, Taniwaki M, Maekawa T. Circulating endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Apr;14(4):426-37. （京都大学輸血細胞治療部、本学循環器内科学教室との共同研究）

Miyagawa M, Minami M, Fujii K, Sendo R, Mori K, Shimizu D, Nakajima T, Yasui K, Itoh Y, Taniwaki M, Okanoue T, Yoshikawa T. Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab. J Med Virol. 2008 Dec;80(12):2069-78. （本学消化器内科学教室との共同研究）

Morimoto Y, Nomura K, Tsutsumi Y, Ohshiro M, Fujimoto Y, Shimizu D, Wakabayashi N, Konishi H, Mitsufuji S, Matsumoto Y, Taniwaki M. Clostridium difficile-associated diarrhea with hematochezia is associated with ulcer formation. Scand J Gastroenterol. 2008 Aug;43(8):967-70. （本学消化器内科学教室との共同研究）

Nakajima T, Yasui K, Zen K, Inagaki Y, Fujii H, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Inazawa J, Okanoue T. Activation of B-Myb by E2F1 in hepatocellular carcinoma. Hepatol Res. 2008 Sep;38(9):886-95. （本学消化器内科学教室との共同研究）

Nomura K, Fujimoto Y, Kanbayashi Y, Ikawa K, Taniwaki M. Pharmacokinetic-pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies. Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1141-3.

Kanbayashi Y, Nomura K, Fujimoto Y, Shimura K, Shimizu D, Okamoto K, Matsumoto Y, Horiike S, Shimazaki C, Takagi T, Taniwaki M. Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. Int J Antimicrob Agents. 2008 May;31(5):452-7.

Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, Kobayashi Y, Kamitsuji Y, Kawata E, Takeuchi M, Murotani Y, Yokota A, Hirai M, Majima S, Taniwaki M, Maekawa T, Kimura S. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res. 2008 Sep;32(9):1462-7. （京都大学輸血細胞治療部との共同研究）

Nomura K, Fujimoto Y, Morimoto Y, Kanbayashi Y, Matsumoto Y, Taniwaki M. Population pharmacokinetics of levofloxacin as prophylaxis for febrile neutropenia. Intern Med. 2008;47(5):375-8. （本学消化器内科学教室との共同研究）

Nomura K, Morikawa N, Ikawa K, Ikeda K, Fujimoto Y, Shimizu D, Taniguchi K, Shimura K, Kanbayashi Y, Komori T, Matsumoto Y, Fujita N, Shimazaki C, Taniwaki M. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother. 2008 Apr;61(4): 892-900.

Wang SF, Aoki M, Nakashima Y, Shinozuka Y, Tanaka H, Taniwaki M, Hattori M, Minato N. Development of Notch-dependent T-cell leukemia by deregulated Rap1 signaling. Blood. 2008 Mar 1;111(5):2878-86.（京都大学免疫細胞生物学教室との共同研究）

Inagaki Y, Yasui K, Endo M, Nakajima T, Zen K, Tsuji K, Minami M, Tanaka S, Taniwaki M, Itoh Y, Arii S, Okanoue T. CREB3L4, INTS3, and SNAPAP are targets for the 1q21 amplicon frequently detected in hepatocellular carcinoma. Cancer Genet Cytogenet. 2008 Jan 1;180(1):30-6. （本学消化器内科学教室との共同研究）

2007年

Kaneko H, Ohkawara T, Aragane H, Ohkawara Y, Taniwaki M. Clinicopathological analysis of a case with mesenteric solitary Castleman's disease: diagnostic value of radiological findings. Int Surg. 2007 Sep-Oct;92(5):272-5.

Kawata E, Kuroda J, Wada K, Yoshida M, Kamiuchi K, Nakayama-Harusato I, Kimura S, Maekawa T, Kitagawa Y. Hypereosinophilic syndrome accompanied by Buerger's disease-like femoral arterial occlusions. Intern Med. 2007;46(23):1919-22.

Kuroda J, Kimura S, Strasser A, Andreeff M, O'Reilly LA, Ashihara E, Kamitsuji Y, Yokota A, Kawata E, Takeuchi M, Tanaka R, Tabe Y, Taniwaki M, Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007 Sep;14(9):1667-77.（京都大学輸血細胞治療部、MD Anderson Cancer Center、The Walter & Eliza Hall Instituteとの共同研究）

Matsumoto Y, Horiike S, Fujimoto Y, Shimizu D, Kudo-Nakata Y, Kimura S, Sato M, Nomura K, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M. Effectiveness and limitation of gamma knife radiosurgery for relapsed central nervous system lymphoma: a retrospective analysis in one institution. Int J Hematol. 2007 May;85(4):333-7.

Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M. Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol. 2007 Apr;85(3):212-8.（本学臨床分子病態・検査医学教室との共同研究）

Kaneko H, Ohkawara Y, Taniguchi K, Matsumoto Y, Nomura K, Horiike S, Yokota S, Taniwaki M. Simultaneous complication of multiple myeloma with Sjögren syndrome. Asian Pac J Allergy Immunol. 2006 Dec;24(4):245-8.

Uchida R, Ashihara E, Sato K, Kimura S, Kuroda J, Takeuchi M, Kawata E, Taniguchi K, Okamoto M, Shimura K, Kiyono Y, Shimazaki C, Taniwaki M, Maekawa T. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface. Biochem Biophys Res Commun. 2007 Mar 9;354(2):613-8. （京都大学輸血細胞治療部との共同研究）

Kobayashi Y, Kamitsuji Y, Kuroda J, Tsunoda S, Uoshima N, Kimura S, Wada K, Matsumoto Y, Nomura K, Horiike S, Shimazaki C, Yoshikawa T, Taniwaki M. Comparison of human herpes virus 8 related primary effusion lymphoma with human herpes virus 8 unrelated primary effusion lymphoma-like lymphoma on the basis of HIV: report of 2 cases and review of 212 cases in the literature. Acta Haematol. 2007;117(3):132-44.

Yokota A, Kimura S, Masuda S, Ashihara E, Kuroda J, Sato K, Kamitsuji Y, Kawata E, Deguchi Y, Urasaki Y, Terui Y, Ruthardt M, Ueda T, Hatake K, Inui K, Maekawa T. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood. 2007 Jan 1;109(1):306-14（京都大学輸血細胞治療部との共同研究）

Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007 Oct;4(10):1681-89.（The Walter & Eliza Hall Instituteとの共同研究）

Ueda Y, Itoh T, Fuji N, Harada S, Fujiki H, Shimizu K, Shiozaki A, Iwamoto A, Shimizu T, Mazda O, Kimura T, Sonoda Y, Taniwaki M, Yamagishi H. Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy. Cancer Immunol Immunother. 2007 Mar;56(3):381-9.（本学消化器内科学教室との共同研究）

2006年

Shimura K, Shimazaki C, Taniguchi K, Akamatsu S, Okamoto M, Uchida R, Nomura K, Inaba T, Horiike S, Kanamura N, Taniwaki M. Hyperbaric oxygen in addition to antibiotic therapy is effective for bisphosphonate-induced osteonecrosis of the jaw in a patient with multiple myeloma. Int J Hematol. 2006 Nov;84(4):343-5.

Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A, Roberts AW, Strasser A. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14907-12. （The Walter & Eliza Hall Institute of Medical Researchとの共同研究）

Okamoto M, Inaba T, Yamada N, Uchida R, Fuchida SI, Okano A, Shimazaki C, Taniwaki M. Expression and role of MHC class I-related chain in myeloma cells. Cytotherapy. 2006;8(5):509-16.（本学臨床分子病態・検査医学教室との共同研究）

Fujimoto Y, Nomura K, Shimizu D, Okuda T, Yoshida N, Matsumoto Y, Taki T, Horiike S, Taniwaki M. Pulmonary relapse of non-Hodgkin's lymphoma in bilateral upper lobes. Intern Med. 2006;45(16):971-3.（本学消化器内科学教室との共同研究）

Taki T, Taniwaki M. Chromosomal translocations in cancer and their relevance for therapy. Curr Opin Oncol. 2006 Jan;18(1):62-8.（本学臨床分子病態・検査医学教室との共同研究）

Kometani K, Aoki M, Kawamata S, Shinozuka Y, Era T, Taniwaki M, Hattori M, Minato N. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model. Cancer Res. 2006 Oct 15;66(20):9967-76.（京都大学免疫細胞生物学教室との共同研究）

Ishida D, Su L, Tamura A, Katayama Y, Kawai Y, Wang SF, Taniwaki M, Hamazaki Y, Hattori M, Minato N. Rap1 signal controls B cell receptor repertoire and generation of self-reactive B1a cells. Immunity. 2006 Apr;24(4):417-27. （京都大学免疫細胞生物学教室との共同研究）

Yoshida N, Nomura K, Wakabayashi N, Konishi H, Nishida K, Taki T, Mitsufuji S, Horiike S, Yanagisawa A, Yamagishi H, Nakamura S, Okanoue T, Taniwaki M. Cytogenetic and clinicopathological characterization by fluorescence in situ hybridization on paraffin-embedded tissue sections of twenty-six cases with malignant lymphoma of small intestine. Scand J Gastroenterol. 2006 Feb;41(2):212-22. （本学消化器内科教室との共同研究）